| |
RA
|
axSpA
|
|---|
|
TNFi until positive pregnancy testa (n = 15)
|
TNFi-negative (n = 60)
|
TNFi until positive pregnancy test (n = 24)
|
TNFi-negative (n = 37)
|
|---|
|
Patients (n) with flare at
|
|
First trimester
|
6
|
4
|
1
|
2
|
|
Second trimester
|
3
|
4
|
5
|
1
|
|
Third trimester
|
1
|
4
|
4
|
2
|
|
Medication at conception
|
|
TNFi
|
15 (100)
|
0 (0)
|
24 (100)
|
0 (0)
|
|
NSAIDs
|
1 (6.7)
|
13 (21.7)
|
11 (45.8)
|
23 (61.2)
|
|
Glucocorticosteroidsb
|
1 (6.7)
|
23 (38.3)
|
2 (8.3)
|
1(3.7)
|
|
DMARDs
|
2 (13.3)
|
27 (45)
|
3 (12.5)
|
2 (5.4)
|
|
SSZ
|
1 (6.7)
|
17(28.3)
|
3 (12.5)
|
2 (5.4)
|
|
HCQ
|
1 (6.7)
|
7 (11.7)
| | |
|
SSZ and HCQ
| |
3 (5)
| | |
|
Medication during pregnancy
|
|
TNFi
|
4 (26.7)
|
5 (8.3)
|
10 (41.7)
|
1 (2.7)
|
|
NSAIDs
|
5 (33.3)
|
23 (38.3)
|
15 (62.5)
|
27 (73)
|
|
Glucocorticosteroidsb
|
7 (46.7)
|
29 (48.3)
|
12 (50.0)
|
3 (8.1)
|
|
DMARDs
|
7 (46.7)
|
38 (63.3)
|
3 (12.5)
|
2 (5.4)
|
|
SSZ
|
1 (6.7)
|
23 (38.3)
|
3 (12.5)
|
2 (5.4)
|
|
HCQ
|
1 (6.7)
|
9 (15)
| | |
|
SSZ and HCQ
|
5 (33.3)
|
6 (10)
| | |
|
Initiation of medication during pregnancy
|
9 (60)
|
16 (26.7)
|
15 (62.5)
|
4 (10.8)
|
|
TNFic
|
4 (26.7)
|
5 (8.3)
|
10 (41.7)
|
1 (2.7)
|
|
Start at visit 1 T-2 T-3 T
|
2-2-0
|
1-3-1
|
4-4-2
|
0-0-1
|
|
Glucocorticosteroidsb
|
5 (33.3)
|
11(18.6)
|
12 (50)
|
3 (8.1)
|
|
Start at visit 1 T-2 T-3 T
|
0-4-1
|
3-6-2
|
4-5-3
|
0-2-1
|
-
Abbreviations: axSpA Axial spondyloarthritis, DMARD Disease-modifying antirheumatic drug, HCQ Hydrochloroquine, NSAID Nonsteroidal anti-inflammatory drug, RA Rheumatoid arthritis, SSZ Sulfasalazine, TNFi Tumor necrosis factor inhibitor, 1 T First trimester, 2 T Second trimester, 3 T Third trimester
- Numbers are count or count (percent); the percentages are calculated for each column
-
aNSAIDs used until gestational week 32
-
bPrednisone or prednisolone
-
cTNFi initiated during pregnancy: 11 certolizumab, 8 etanercept, 1 adalimumab
